characteristics, limitations and future perspectives of viral vector transduction curr gene ther studeny m, marini fc, dembinski jl, zompetta c, cabreirahansen m, bekele bn, why levothyroxine is bad champlin re and andreeff m mesenchymal stem cells potential precursors for tumor stroma and targeteddelivery vehicles for anticancer agents j natl cancer inst ehtesham m, why levothyroxine is bad kabos p, kabosova a, neuman t, black kl and yu js the use of interleukin secreting neural stem cells for the treatment of intracranial glioma why levothyroxine is bad cancer res su l, lee r, bonyhadi m, matsuzaki h, forestell s, escaich s, bohnlein e and kaneshima h hematopoietic stem cellbased gene therapy for why levothyroxine is bad acquired immunodeficiency syndrome efficient transduction and expression of revmlo in myeloid cells in vivo and in vitro blood sunkomat jn and gaballa ma stem cell therapy why levothyroxine is bad in ischemic heart disease car diovasc drug rev huber a, padrun v, deglon n, aebischer p, mohler h and boison d grafts of adenosinereleasing cells why levothyroxine is bad suppress seizures in kindling epilepsy proc natl acad sci usa boison d, huber a, padrun v, deglon n, aebischer p and mohler h seizure suppression why levothyroxine is bad by adenosinereleasing cells is independent of seizure frequency epilepsia shao j, dehaven j, lamm d, weissman dn, malanga cj, rojanasakul y and ma jk b why levothyroxine is bad a cellbased drug delivery system for lung targeting ii therapeutic activities on bf melanoma in mouse lungs drug del alby l and auerbach r differential why levothyroxine is bad adhesion of tumor cells to capillary endothelial cells in vitro proc natl acad sci usa cochleates as nanoparticular drug carriers leila zarif introduction in spite of why levothyroxine is bad the availability of many nontraditional novel dosage forms, oral route remains the most attractive way for administration of therapeutical materials however, many therapeutic agents, especially why levothyroxine is bad the increasing number of biological molecules cannot be taken up by intestine due to their intrinsic impermeability to tissue membranes and the enzymatic degradation through why levothyroxine is bad the wall of the gi tract carrier systems that facilitate intestine uptake of these molecules are of major interests in the drug delivery arena moreover, drug delivery systems that provide a route of administration that does not involve injection can improve patient compliance and expand the market for existing, injectable, drugs why levothyroxine is bad the factors which are important for the oral efficiency of a vehicle system have been repeatedly summarized in the literature, small particle size, appropriate surface why levothyroxine is bad properties, mucoadhesive and targeting moieties, stability, as well as dose are the major factors imparting the efficiency of oral uptake producing formulations of poorly soluble drugs with high bioavailability is an even higher challenge known technologies are nanocrystals and nanoparticles which use the approach of enhancing the bioavailability by a why levothyroxine is bad decrease in particle size, resulting in an increase of surface area and subsequently a faster dissolution other technologies such as solid dispersions, polymeric micelles and why levothyroxine is bad self emulsifying systems were developed to increase the drug solubility many lipidbased systems were developed to enhance oral bioavailability, examples are lipidbased emulsions & microemulsions solid lipid nanoparticles sln, a high melting point lipids enclosed in a surfactant layer, adequate to enhance the oral bioavailability of poorly absorbed drugs lipid nanocapsules why levothyroxine is bad lnc for oral, injectable use and improved bioavailability lipid nanospheres prepared from egg lecithin and soybean, described for their low toxicity and higher efficacy, compared why levothyroxine is bad with other delivery systems when incorporating amphotericin b, due to their smaller particle size and lower uptake by reticuloendothelial system, recently, solid lipid microparticles, prepared why levothyroxine is bad by the solventinwater emulsiondiffusion technique, were described for the encapsulation and oral delivery of insulin in particular, lipidbased cochleate delivery system appears to provide answers to why levothyroxine is bad oral delivery challenges by formulating different kind of molecules, especially hydrophobic ones, and protecting the sensitive and biologically active molecules from harsh environmental conditions in why levothyroxine is bad this review, we will focus on cochlea tes nanoparticular drug carrier and will present the main features and the state of the art of this why levothyroxine is bad delivery technology cochleates nanoparticles in oral delivery cochleate structure cochleates were first described by dimitrious papahadjopoulos and his coworkers in as precipitates formed by the why levothyroxine is bad interaction of negatively charged phos phatidylserine and calcium he named these cylindrical structures cochleate, meaning shell in the greek language because of their rolledup form, why levothyroxine is bad and explained the mechanism of cochleates formation by the fusion of negatively charged vesicles induced by the calcium cation fig these cigarlike structures have gained interest why levothyroxine is bad as antigen delivery system for vaccine applications more recently cochleates were studied as tools to deliver small molecule drugs a cochleate lipid formulation of amphotericin why levothyroxine is bad � has been developed as an oral composition to treat systemic fungal infections other medical and nonmedical applications are also under investigation cochleate preparation which why levothyroxine is bad phospholipid and which cation to use cochleates are a phospholipidion precipitates does that mean that cochleate is a structure obtained from precipitation of any phospholipid why levothyroxine is bad with any ion as presented in some litterature?, ie a complex of negatively charged phospholipid with any cation or a complex made from a positively charged why levothyroxine is bad lipid with any anion � � c � cs fl fusion i ���� {rrirfij ���def fig cochleate cylindrical structure and mechanism of formation adapted from why levothyroxine is bad refs and with permission papahadjopoulos has given in this appellation to a rolled phospholipid structure so far, to our knowledge no physicochemical evidence on the why levothyroxine is bad obtention of such cigarlike structure from positively charged phospholipid with an anion had been described on the contrary, extensive litterature is available on obtaining these why levothyroxine is bad cigarlike structure when negatively charged phospholipid such as phosphos phatidylserine ps had been precipitated with a cation such as calcium other negatively charged phospholipids, such why levothyroxine is bad as phosphatidic acid pa or phosphatidyl glycerol derivatives, have been studied as well mixture of negatively charged phospholipids with other lipids can lead to cochleate formation why levothyroxine is bad in this case, the cochleate formation depends on the negatively charged lipidother lipid ratio and depends on the nature of the negatively charged lipid in why levothyroxine is bad the mixed upid system for example, pa derivatives form cochleate domains after the addition of calcium cation however, when mixed with the corresponding diacylphosphatidyl choline pc and diacylphosphatidylethanolamine pe, it was found that up to mole of pc or pe can be introduced into the cochleate phase of paca, above which a distinct pc rich or perich phase appears other phospholipid derivatives such as galactosphingolipid hydroxy fatty acid cerebroside were reported to form cochleate cylinders by why levothyroxine is bad thermal mechanical treatment of glycol suspensions however, the addition of conjugated lipid, such as polyethylene glycollipid conjugates to ps vesicles, inhibited the calciuminduced fusion in why levothyroxine is bad general, an additional desired feature of an oral drug delivery system is that the excipient permitting this transport to be classified is generally regarded as why levothyroxine is bad safe gras soy phosphatidylserine fits this criteria furthermore, soy ps has been used as a nutrient supplement since early s clinical trials showed that ps why levothyroxine is bad may play a role in supporting mental functions in aging brains such as enhancing the memory, improving learning ability, reducing the stress and anxiety cochleates why levothyroxine is bad can be made from purified soy phosphatidylserine, which represents an affordable source of raw material a study comparing the purified soy phosphatidylserine psps to nonpurified soy why levothyroxine is bad ps npsps has been disclosed in this patent, showing that ps should be present in an amount of at least of the total lipid in why levothyroxine is bad order to allow the formation of cochleates the other phospholipids present can be selected either from the anionic group such as phosphatidic acid, phosphatidylglycerol, phosphatidyl why levothyroxine is bad inositol or phosphatidylcholine psps cochleates can be loaded with different bioactive materials such as nutritional supplement, vitamins, antiviral, antifungal, small peptides proof of principle of why levothyroxine is bad the use of purified soy ps has been achieved using a polyene antifungal agent, amphotericin b the preparation method for amphotericin � cochleates can be either why levothyroxine is bad via high phtrapping or film method or by hydrogel method the latter leading to nanocochleates formation the nature of the cation is an important factor why levothyroxine is bad in cochleate formation in the precipitation process, divalent cations are preferred to monovalent cations monovalent cations such as na were described to prevent the cochleate why levothyroxine is bad formation increases concentration of na ions was shown to interfere with the destabiliza tion effect of ca a critical caps ratio is necessary for the why levothyroxine is bad destabilization effect of divalent cations and the formation of cochleate phases the formation of cochleate is easier from small unilamellar vesicles suv however, multilamellar vesicles why levothyroxine is bad mlv can also lead to cochleate formation in this case, the first mechanism is a destabilization of the outer bilayer of ps by ca which causes why levothyroxine is bad its collapse, leading to a higher access of ca to inner ps bilayers and so forth which molecules can be entrapped in cochleates nanoparticles due why levothyroxine is bad to the intrinsic nature of the lipidcontained cochleates, these nanoparticles can encapsulate a variety of molecules of all shapes and sizes preference is given, however, why levothyroxine is bad to hydrophobic molecules, for which a need to enhance chemical stability or bioavailability is desired [fig a], amphiphatic molecules which can easily d positively charged why levothyroxine is bad moiety ca co co co hydrophobic i molecule ca co co co i amphlpathic molecule i co co co co negatively charged moiety co co ca� sa ipf ff ff ii i i m ca ca ca ca caca ca ca ca ca ca ca ������������������ qg qq ���� co � why levothyroxine is bad i � � i co co co ca fig type of molecules which can be encapsulated into lipid based cochleate adapted from ref with permission insert in the membrane bilayers [fig b], negatively charged moiety [fig c] or positively charged moiety [fig d] could be encapsulated in the cochleate nanoparticle why levothyroxine is bad structure the nature of the drug influence the percentage of encapsulation hydrophobic drug shows a quantitative encapsulation, whereas less was seen for amphiphatic molecules for why levothyroxine is bad instance, doxorubicin which presents hydrophobic regions is a watersoluble drug, has a partition between the bilayers and the external aqueous phase [fig b] as calcium induces why levothyroxine is bad dehydration of the interbilayer domains, the amount of water in this region is low, therefore, small hydrophilic molecules will not be suitable for cochleate system why levothyroxine is bad multiple ways of preparing cochleates ca ca ca co several processes were developed to obtain cochleates with a nanosize range, with the objective to allow why levothyroxine is bad oral delivery, particle size is process dependent when a small nanosized particle is desired, the hydrogel method can be used, based on the use of why levothyroxine is bad an aqueousaqueous emulsion system briefly, this method consists of steps the preparation of small size liposomes either by high ph method, or by film method, why levothyroxine is bad then the liposomes are mixed with a high viscosity polymer such as dextran the dextranliposome phase is then injected into a second, non miscible, polymer ie why levothyroxine is bad peg the calcium was then added and diffused slowly from one phase to another, resulting in the formation of nanocochleates the final step is the why levothyroxine is bad washing of the gel these nanosized cochleates showed potential in the oral delivery of drugs electron microscopy and xray crystallography of the nanoparticles show a why levothyroxine is bad unique multilayered structure consisting of continuous, solid lipid bilayer sheets, rolled up in a spiral with no internal aqueous space and the localization of amb in the lipid bilayer other preparation techniques are known, eg the trapping method, useful for the encapsulation of hydrophilic and hydrophobic molecules which consist in the why levothyroxine is bad preparation of the liposomal suspension containing the drug either in the aqueous space of liposome when hydrophilic or intercalated in between the bilayers when hydrophobic a step of addition of calcium follows, and an aggregate of cochleates are formed the cochleates made by the trapping method present higher aggregation compared why levothyroxine is bad with other methods this has been demonstrated using electron microscopy after freezefracture another method was developed for hydrophobic drugs, known as the solvent drip method why levothyroxine is bad which consists of preparing a liposomal suspension separately based on soy ps and a hydrophobic or amphipathic cargo moiety solution solvent for hydrophobic drug can why levothyroxine is bad be selected from dmso, dmf the solution is then added to liposomal suspension since the solvent is miscible in water, a decrease of the solubility of why levothyroxine is bad the cargo moiety is observed, which associates at least in part with the lipidhydrophobic liposomal bilayers the cochleates are then obtained by addition of calcium why levothyroxine is bad and the excess solvent is being washed usually, the cochleate formation can be characterized by optical microscopy when they are present in needle form review ryobi 4 volt lithium screwdriveer in why levothyroxine is bad the micrometer size range in this case, direct observation using a higher magnification can be used when nanocochleate are obtained, optical microscope can be used why levothyroxine is bad as an indirect method to assess the formation of cochleate, ie observation of the liposome formation after chelation of the calcium present, by addition of edta why levothyroxine is bad ethylene diamine tetraacetate to nanocochleate a more sophisticated method is the electron microscopy after freeze fracture, which allows the observation of the tighted packed bilayers why levothyroxine is bad recently, other methods were described using laurdan dodecanoyldimethylamino naphtalene to monitor the cochleate phase formation in this case, the lipid vesicles are labeled with laurdan why levothyroxine is bad and the addition of calcium to the laurdan labeled vesicles resulted in a shift in the emission peak maximum of laurdan due to dipolar relaxation, why levothyroxine is bad excitation and emission, generalized polarization gpex and gpem indicates the transition from a lc to a rigid and dehydrated cochleate phase cochleates as oral delivery system for antifungal agent, amphotericin � among the drug of choice using nanocochleate delivery system, amphotericin � amb presented all aspects of a good candidate amphotericin why levothyroxine is bad � is a hydrophobic drug with poor oral bioavailability this drug had been used for decades in injectable form to treat systemic fungal infections of why levothyroxine is bad candida, cryptococcus and aspergillosis species lipid formulations of amphotericin � why would men use clomid such as liposomes, lipid complexes, lipid emulsions and colloidal dispersions, were developed with the aim to achieve a higher therapeutic index, these formulations indeed showed enhanced therapeutic index, even though none of these formulations showed ability to deliver amb orally why levothyroxine is bad cocheate technology seems to offer the advantage over other delivery systems in providing the possibility for the oral delivery of amb oral administration of amphotericin � why levothyroxine is bad cochleates camb to healthy mice achieved potentially therapeutic concentrations in key target tissues preclinical studies demonstrate a promising activity of camb in murine models of why levothyroxine is bad clinically relevant invasive fungal infections such as disseminated candidiasis, disseminated aspergillosis, and central nervous system cryptococcosis in candidiasis animal model in candida albicans infected murine why levothyroxine is bad animal model, amb cochleates showed potential either after intraperitoneal ip or oral po administration after ip administration camb provided protection against c albicans at doses why levothyroxine is bad as low as mgkgday, kidney tissues burden showed that camb was more potent than fungizone� at mgkgday and was equivalent to ambisome� at mgkgday fig why levothyroxine is bad camb was also effective after oral administration complete eradication of c albicans from the lungs was noticed after po administration at mgkgday these results were comparable why levothyroxine is bad to ip fungizone� at mgkgday in aspergillosis animal model oral administration of camb was shown to be protective in a dose dependent manner against systemic why levothyroxine is bad infection of aspergillus fumigatus in animals immunosusppressed with cyclophosphamide, in this mouse model, intragastric administration of camb at mgkgday for days resulted in survival, while why levothyroxine is bad fungizone at mgkgday ip resulted in survival higher doses of fungizone were lethal to animals s ?st w j t � �� �ft t � � o u � � o� � �� oo� t control atnb dose concentration mgkg fig kidneys tissue burden of infected mice treated with either camb , fungizone ?